Supplemental
Capital Expenditures Incurred but Not Yet Paid
West Pharmaceutical Services Capital Expenditures Incurred but Not Yet Paid increased by 866.7% to $26.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 30.4%, from $37.50M to $26.10M. Over 3 years (FY 2021 to FY 2024), Capital Expenditures Incurred but Not Yet Paid shows an upward trend with a 11.6% CAGR.
Analysis
StatementCash Flow Statement
SectionSupplemental
First reportedQ1 2013
Last reportedQ1 2026Apr 23, 2026
Metric ID:
orcl_unpaid_capital_expendituresHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.28M | $10.28M | $10.28M | $8.30M | $8.30M | $8.30M | $8.30M | $13.33M | $13.33M | $13.33M | $13.33M | $45.70M | $0.00 | $8.70M | $2.70M | $37.50M | $2.70M | $26.10M |
| QoQ Change | — | +0.0% | +0.0% | -19.2% | +0.0% | +0.0% | +0.0% | +60.5% | +0.0% | +0.0% | +0.0% | +243.0% | -100.0% | — | -69.0% | >999% | -92.8% | +866.7% |
| YoY Change | — | — | — | — | -19.2% | -19.2% | -19.2% | +60.5% | +60.5% | +60.5% | +60.5% | +243.0% | -100.0% | -34.7% | -79.7% | -17.9% | -69.0% | -30.4% |
Range$0.00 – $45.70M
CAGR+24.5%
Avg YoY Growth+6.8%
Median YoY Growth-19.2%
Capital Expenditures Incurred but Not Yet Paid at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's capital expenditures incurred but not yet paid?
- West Pharmaceutical Services (WST) reported capital expenditures incurred but not yet paid of $26.10M in Q1 2026.
- How has West Pharmaceutical Services's capital expenditures incurred but not yet paid changed year-over-year?
- West Pharmaceutical Services's capital expenditures incurred but not yet paid decreased by 30.4% year-over-year, from $37.50M to $26.10M.
- What is the long-term trend for West Pharmaceutical Services's capital expenditures incurred but not yet paid?
- Over 3 years (2021 to 2024), West Pharmaceutical Services's capital expenditures incurred but not yet paid has grown at a 11.6% compound annual growth rate (CAGR), from $41.10M to $57.10M.